SUMMARY The current methods of treating and reporting non-specific genital infection (NSGI) are described. The most commonly used drug was tetracycline in one or other form. Epidemiological treatment was widely used, particularly for female sexual contacts. There was considerable variation in the reporting criteria for the quarterly returns. The establishment of acceptable and uniform criteria for notification of NSGI is discussed.
Introduction
Part 1 of this paper (Adler, 1978a) was concerned with the current methods of, and criteria for, diagnosis of non-specific genital infection (NSGI) used by consultants in England and Wales. The second part describes treatment and reporting criteria.
Results

TREATMENT FOR NSGI
Curative treatment with antibiotics Table 1 shows the various types of treatment given to male patients with NSU. In 158 (92%) clinics consultants treating male patients used a singledrug regimen. It was rare for a combination of drugs to be used. Tetracycline in one or other form was used in all the clinics in which a singledrug regimen was prescribed. For male patients the most commonly prescribed drugs were oxytetracycline or tetracycline, which were used in 92 (54%) clinics. Oxytetracycline was given by physicians in 65 clinics and tetracyline in 27, the daily dose ranging from 0 5-2-0 g. The next most frequently used preparation was triple tetracycline (Deteclo), the doses ranging from 600 mg-1-2 g per day. The Figure shows the number of days for which oxytetracycline or tetracycline and triple tetracycline were prescribed. The most commonly used daily dosage of oxytetracycline or tetracycline was 1 g per day in either two or four divided doses (76 clinics). The most popular regimen was 1 g daily for five days followed by the same dose for seven days. In some clinics the daily dose of 1 g was prescribed for four days or, at the other extreme for 21 days. In other clinics the daily dosage was higher at 2 g and was prescribed for a period ranging from seven to 14 days. The most frequent daily dosage of triple tetracycline was 600 mg, which was used in 36 clinics. The most common period for which this dose was prescribed was seven days (13 clinics) followed by 21 days (11 clinics). In some clinics a daily dose of 1 -2 g was prescribed for a period of five days (seven clinics) or 21 days (one clinic). Triple tetracycline (mg)
Figure Dosage and number of days for which oxytetracycline and tetracycline and triple tetracyline were prescribed
The treatment prescribed for female patients is shown in Table 2 . The treatment, whether given epidemiologically or because the physician recognised NSGI as a distinct entity, was similar and has therefore not been separated. The types of drugs, daily dosage, and period for which they were prescribed were similar to those given to male patients. A single-drug regimen was used in most clinics (89 %) and, apart from three clinics which used either co-trimoxazole (two clinics) or ampicillin (one clinic), the drug of choice was tetracycline in one or other form. The most commonly prescribed drugs were tetracycline or oxytetracycline, which were used in 90 (52 %) clinics, followed by triple tetracycline in 56 (320%) clinics. The daily dosage for these two drugs was the same as that given to male patients. (Table  4) . In 80 % of clinics only one of the specified reasons was given for epidemiological treatment of contacts of NSU, in 13 % two were given, and in the remaining 7 % three or more. Ureaplasma, etc.) . It was also considered of interest, however, to establish the eventual diagnosis of a patient who had been treated epidemiologically but for whom tests gave negative results. Table 5 shows the diagnostic categories for sexual contacts treated epidemiologically which were used by consultants when the smears gave negative results according to the criteria normally used to establish the diagnosis. In most clinics (60%) in which this approach was used for female or passive homosexual contacts, the diagnosis and subsequent notification of 'non-specific genital infection' (Department of Health and Social Table 6 . The commonest reason was that alcohol irritates the urethra and increases the severity of the symptoms. This differed from the reason that alcohol causes a relapse, which was the second most commonly cited reason. In two-thirds of clinics one of the reasons was specified and in the remaining third two of them. 
Quarterly returns for NSGI
The criteria used by physicians to establish a diagnosis of NSU in male heterosexual and active homosexual patients, of NSGI in female patients, and of non-specific proctitis in passive homosexuals have been described in part 1 of this paper (Adler, 1978a , Tables 1-3) . In all clinics where microscopy was used a return was made for patients with NSU on the basis of this procedure, in which the quantitative and qualitative criteria for the leucocytes were applied which non-specific proctitis was recognised as a distinct clinical entity in passive homosexuals when the patient received treatment. The criteria for establishing the diagnosis of non-specific proctitis also varied, and again it was possible for a consultant to make a return on the basis of microscopical evidence, clinical examination, or history alone.
In addition to the returns made for male and female patients on the basis of the established criteria, cases were also classified as NSGI if treated epidemiologically. In 60%0 of clinics which used this approach and in which no definitive disease had been diagnosed, returns were made as if the patient had NSGI.
Discussion
The variation among physicians in establishing a diagnosis of NSU, NSGI, and non-specific proctitis is inevitably reflected in the quarterly returns to the DHSS. This variation is further complicated by two other factors.
Firstly, even though all the conditions are potentially different entities the standard notification form (SBH 60) does not allow for this distinction. Consultants have to include all categories under the same heading of NSGI and can only divide patients by sex. This lack of distinction means that a nebulous mixture of cases is included. This is made even worse when the DHSS adds new categories of cases that require notification without provision for their separation. This occurred in 1971 when physicians were required to make returns for the first time for cases of NSGI in women and of non-specific proctitis. Instead of being notified separately, they are all returned as cases of NSGI. This has made it even harder to judge whether the increase in the number of cases of NSGI is real or apparent owing to the addition of new entities that cannot be separated from the general rubric of NSGI.
Secondly, a further problem of notification occurs when a patient is treated epidemiologically without any evidence of disease. At present physicians working in 60% of clinics where such treatment is used for patients without positive findings on microscopy, culture, clinical examination, or history are notifying these as 'true' cases ot NSGI. This is contrary to what is believed by the Chief Medical Officer (DHSS, 1970) , who stated that all female patients treated for epidemiological reasons should appear under the category 'other conditions requiring treatment' (D2). Because such patients are included as 'true' cases the annual number of notified cases of NSGI contains two types; firstly, those in whom a diagnosis has been made on the basis of a set of diagnostic criteria, however variable; and, secondly, those who are sexual contacts but have no evidence of disease and fulfil no diagnostic criteria. One course of action would be to include all cases treated epidemiologically as 'other conditions requiring treatment' (D2). This may appear tidy but will only make this category even more of a dumping ground than it is already. For instance, most consultants who treat sexual contacts with gonorrhoea on epidemiological grounds use this category (Adler, 1978b) . The other option is for all such cases to be returned as 'non-specific genital infection' with a clear indication that they have been treated epidemiologically in the absence of positive findings. This would necessitate redesigning the SBH 60.
In part 1 of this paper, the question was raised as to whether NSGI in women and non-specific proctitis in homosexuals actually exist as distinct entities. It is probable that the majority of cases of NSGI returned for female patients are in fact those treated epidemiologically and not those patients in whom a primary diagnosis is made. If one accepts that NSGI in women and non-specific proctitis in homosexuals may not exist the most logical approach is to have a separate category for cases treated epidemiologically, and since it is unlikely that physicians see many cases of NSGI in women and proctitis in homosexuals a return could be made for these cases as 'other conditions requiring treatment' (D2).
Virtually all the clinics which treated male and female patients used some form of tetracycline preparation, the most popular ones being oxytetracycline, tetracycline, and triple tetracycline. These drugs accounted for over 80 % of all treatment regimens. The most common daily dosage of tetracycline or oxytetracycline was 1 g for five to seven days; however, some physicians prescribed treatment for two to three weeks. This longer period may have been because the patient was Chlamydiapositive or because it was considered that a better cure rate could be obtained. The latter possibility has been suggested by John (1971) but since disputed by several authors (Willcox, 1972; Helmy and Fowler, 1975; Grimble and Amarasuriya, 1975) . There would appear to be no justification for prescribing tetracycline or oxytetracycline for more than five to seven days unless a clear diagnosis of chlamydial infection has been made.
Triple tetracycline can also be used in the treatment of NSU, and in the present study the most frequently used dosage in clinics was 600 mg a day for five to seven days. Some authors have suggested that triple tetracycline is more effective than oxytetracycline in the treatment of NSU (Bhattacharyya and Morton, 1973) , but this is disputed by other workers (Willcox, 1972; Grimble and Amarasuriya, 1975) . These conflicting reports indicate that no good scientific evidence exists for the use of triple tetracycline in preference to tetracycline. Furthermore, triple tetracycline is more expensive. The average cost to the health service of a prescription dispensed by a retail pharmacist for a five-day course of oxytetracycline at a dose of 1 g per day is £0E32 compared to £0-63 for a five-day course of triple tetracycline at a dose of 600 mg daily, a cost difference of £031 or 97% (Department of Health and Social Security, 1976 
